Infinity Pharmaceuticals, Inc. (INFI): Price and Financial Metrics


Infinity Pharmaceuticals, Inc. (INFI): $0.60

-0.02 (-2.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INFI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

INFI POWR Grades

  • Growth is the dimension where INFI ranks best; there it ranks ahead of 96.33% of US stocks.
  • INFI's strongest trending metric is Value; it's been moving up over the last 179 days.
  • INFI ranks lowest in Momentum; there it ranks in the 5th percentile.

INFI Stock Summary

  • For INFI, its debt to operating expenses ratio is greater than that reported by just 5.21% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 13.84 for INFINITY PHARMACEUTICALS INC; that's greater than it is for 96.1% of US stocks.
  • With a year-over-year growth in debt of -54.46%, INFINITY PHARMACEUTICALS INC's debt growth rate surpasses merely 4.75% of about US stocks.
  • Stocks that are quantitatively similar to INFI, based on their financial statements, market capitalization, and price volatility, are XCUR, PRQR, DARE, IMGN, and GERN.
  • Visit INFI's SEC page to see the company's official filings. To visit the company's web site, go to www.infi.com.

INFI Valuation Summary

  • In comparison to the median Healthcare stock, INFI's price/sales ratio is 327.45% higher, now standing at 21.8.
  • INFI's price/sales ratio has moved up 20.3 over the prior 243 months.

Below are key valuation metrics over time for INFI.

Stock Date P/S P/B P/E EV/EBIT
INFI 2023-01-30 21.8 -5.0 -1.2 -0.2
INFI 2023-01-27 22.9 -5.3 -1.2 -0.2
INFI 2023-01-26 23.2 -5.3 -1.2 -0.2
INFI 2023-01-25 22.6 -5.2 -1.2 -0.2
INFI 2023-01-24 23.2 -5.3 -1.2 -0.2
INFI 2023-01-23 24.2 -5.6 -1.3 -0.3

INFI Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at -50326.14%.
  • The 5 year price growth rate now stands at -45.11%.
  • The 3 year net cashflow from operations growth rate now stands at -265.39%.
Over the past 49 months, INFI's revenue has gone down $19,499,000.

The table below shows INFI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2.501 -43.249 -46.79
2022-06-30 2.217 -41.71 -46.786
2022-03-31 2.043 -40.683 -46.069
2021-12-31 1.858 -40.618 -45.262
2021-09-30 1.843 -39.41 -44.21
2021-06-30 1.911 -39.431 -43.031

INFI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • INFI has a Quality Grade of F, ranking ahead of 2.75% of graded US stocks.
  • INFI's asset turnover comes in at 0.021 -- ranking 367th of 682 Pharmaceutical Products stocks.
  • PALI, ATHX, and SIGA are the stocks whose asset turnover ratios are most correlated with INFI.

The table below shows INFI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.021 1 14.259
2021-06-30 0.025 1 -11.302
2021-03-31 0.028 1 -5.072
2020-12-31 0.036 1 -2.864
2020-09-30 0.032 1 -2.231
2020-06-30 0.027 1 -2.017

INFI Price Target

For more insight on analysts targets of INFI, see our INFI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.29 Average Broker Recommendation 1.44 (Moderate Buy)

INFI Stock Price Chart Interactive Chart >

Price chart for INFI

INFI Price/Volume Stats

Current price $0.60 52-week high $1.76
Prev. close $0.62 52-week low $0.44
Day low $0.60 Volume 270,900
Day high $0.62 Avg. volume 425,519
50-day MA $0.58 Dividend yield N/A
200-day MA $0.86 Market Cap 53.98M

Infinity Pharmaceuticals, Inc. (INFI) Company Bio


Infinity Pharmaceuticals, Inc. discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company was founded in 2001 and is based in Cambridge, Massachusetts.


INFI Latest News Stream


Event/Time News Detail
Loading, please wait...

INFI Latest Social Stream


Loading social stream, please wait...

View Full INFI Social Stream

Latest INFI News From Around the Web

Below are the latest news stories about INFINITY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate INFI as an investment opportunity.

Have you been able to find a good deal on Infinity Pharmaceuticals Inc.’s shares?

A share of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) closed at $0.71 per share on Friday, up from $0.68 day before. While Infinity Pharmaceuticals Inc. has overperformed by 4.81%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -51.86%, with highs and lows ranging from $1.76 […]

US Post News | January 17, 2023

How should investors view Infinity Pharmaceuticals Inc. (INFI)?

The share price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) rose to $0.57 per share on Tuesday from $0.56. While Infinity Pharmaceuticals Inc. has overperformed by 2.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -74.67%, with highs and lows ranging from $2.41 to $0.44, […]

US Post News | January 4, 2023

Analysts Predict A Surge In Infinity Pharmaceuticals Inc. (NASDAQ: INFI)?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) shares, rose in value on Thursday, December 29, with the stock price up by 0.17% to the previous day’s close as strong demand from buyers drove the stock to $0.50. Actively observing the price movement in the recent trading, the stock is buoying the session at $0.49, falling within a range … Analysts Predict A Surge In Infinity Pharmaceuticals Inc. (NASDAQ: INFI)? Read More »

Stocks Register | December 29, 2022

Results from Infinity Pharmaceuticals Inc. (INFI) show potential

The share price of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) rose to $0.54 per share on Friday from $0.52. While Infinity Pharmaceuticals Inc. has overperformed by 4.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INFI fell by -78.83%, with highs and lows ranging from $2.62 to $0.44, […]

US Post News | December 27, 2022

Infinity Pharmaceuticals Inc. (NASDAQ: INFI)’s Stock Market Position Could Improve In The Coming Months

In the last trading session, 1.22 million shares of the Infinity Pharmaceuticals Inc. (NASDAQ:INFI) were traded, and its beta was 1.24. Most recently the company’s share price was $0.54, and it changed around $0.02 or 4.05% from the last close, which brings the market valuation of the company to $46.39M. INFI currently trades at a … Infinity Pharmaceuticals Inc. (NASDAQ: INFI)’s Stock Market Position Could Improve In The Coming Months Read More »

Marketing Sentinel | December 27, 2022

Read More 'INFI' Stories Here

INFI Price Returns

1-mo -6.25%
3-mo -49.58%
6-mo -47.83%
1-year -53.13%
3-year -55.56%
5-year -69.54%
YTD 8.11%
2022 -75.33%
2021 6.13%
2020 120.83%
2019 -18.64%
2018 -41.87%

Continue Researching INFI

Here are a few links from around the web to help you further your research on Infinity Pharmaceuticals Inc's stock as an investment opportunity:

Infinity Pharmaceuticals Inc (INFI) Stock Price | Nasdaq
Infinity Pharmaceuticals Inc (INFI) Stock Quote, History and News - Yahoo Finance
Infinity Pharmaceuticals Inc (INFI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.867 seconds.